Elevated C-reactive protein has been linked to a surprisingly wide range of cancers, including colorectal, lung, breast, ovarian, kidney, bladder, and prostate cancers, as well as blood cancers like myeloma and lymphoma. CRP is a protein your liver pumps out whenever your body senses inflammation, and because chronic low-grade inflammation appears to help tumors take root and grow, researchers have spent decades tracking the overlap between high CRP and cancer diagnoses. The relationship is not the same for every cancer type, though, and in some cases CRP’s value shows up less in predicting who gets cancer and more in predicting how that cancer will behave once it arrives.
Colorectal Cancer
Colorectal cancer has one of the strongest and most studied links to pre-diagnosis CRP. A large nested case-control study published in JAMA found that people who later developed colon cancer had notably higher CRP levels years before their diagnosis compared with matched controls. Those in the highest quarter of CRP concentrations had roughly two and a half times the odds of developing colon cancer compared with people in the lowest quarter, and among nonsmokers the association was even steeper, with odds roughly three and a half times higher.1JAMA. C-Reactive Protein and the Risk of Incident Colorectal Cancer An important nuance: that study found the link held for colon cancer specifically but not for rectal cancer, where CRP levels in future patients were essentially the same as in controls.
A more recent meta-analysis pooling data from nearly 800,000 participants confirmed the overall pattern, reporting about a 26 percent increase in colorectal cancer risk among people with elevated CRP.2PubMed. A predictive role of C-reactive protein in colorectal cancer risk: an updated meta-analysis from 780,985 participants and 11,289 cancer cases That said, the dose-response relationship was not straightforward: the risk did not climb in a smooth, predictable way for every incremental rise in CRP. This hints that there may be a threshold effect rather than a linear one, meaning that once CRP crosses a certain level the risk jumps, but further increases do not keep piling on additional risk at the same rate.
Genetics-based research has tried to untangle whether CRP itself is doing the damage or merely tagging along with other risk factors. A Mendelian randomization study in postmenopausal women found that the relationship between genetically elevated CRP and colorectal cancer risk shifted depending on lifestyle factors like smoking, obesity, and hormone therapy use, suggesting the connection between CRP and this cancer is real but heavily modified by what else is going on in a person’s body.3Cancer Research. Abstract 825: Genetically determined elevated C-reactive protein levels and chronic inflammation status associated with primary colorectal cancer risk
Lung Cancer
Lung cancer shows a clear association with elevated CRP, though disentangling CRP from smoking is a persistent challenge. A large prospective study found that people with CRP levels in the highest quarter had roughly double the risk of developing lung cancer compared with those in the lowest quarter. The association was strongest for squamous cell carcinomas of the lung and appeared most clearly in people diagnosed two to five years after their blood was drawn, suggesting it was not simply a matter of an undiagnosed tumor already driving CRP upward.4PubMed Central. C-Reactive Protein and Risk of Lung Cancer
Mendelian randomization work, which uses genetic variants to approximate a lifelong experiment, has found modest but consistent evidence that CRP itself contributes to lung cancer risk. One such study identified links between genetically predicted CRP and overall lung cancer, squamous cell carcinoma, and small-cell lung cancer. However, when the analysis accounted for smoking and body mass index at the same time, some of those associations weakened, meaning at least part of what looks like a CRP effect is actually a smoking or obesity effect echoing through inflammation.5PubMed. Genetic correlation and causal associations between circulating C-reactive protein levels and lung cancer risk The practical upshot is that high CRP in a current or former smoker is a meaningful signal worth paying attention to, but quitting smoking would do far more to lower lung cancer risk than trying to lower CRP alone.
Breast Cancer and the Body Weight Connection
The link between CRP and breast cancer is one of the more conditional relationships in this field. Studies consistently find no significant association between CRP and breast cancer risk in the general female population. But when you narrow the focus to women who are overweight or obese, CRP suddenly matters a great deal. A study from the large French E3N cohort found that among women with a BMI of 25 or above, those with the highest CRP levels had about 92 percent greater odds of breast cancer compared with those with the lowest levels. In women of normal weight, no such relationship existed.6PubMed. C-reactive protein and postmenopausal breast cancer risk: results from the E3N cohort study
A prospective cohort study reinforced this pattern by looking at the combination of high BMI and high CRP together. Women who had both a high BMI and high CRP had about 75 percent greater risk of postmenopausal breast cancer compared with women who had both a low BMI and low CRP.7PubMed Central. Association between body mass index combined with high-sensitivity C-reactive protein and the risk of postmenopausal breast cancer: A prospective cohort study This makes biological sense: excess fat tissue is itself a source of inflammatory signaling, and CRP appears to amplify or interact with that process. Lab research has shown that some aggressive breast cancer cells actually produce their own CRP, and knocking out that CRP production reduced their ability to proliferate and form tumors in animal models.8Biomolecules & Therapeutics. C-Reactive Protein Signaling Pathways in Tumor Progression – Section: BREAST CANCER
Ovarian and Other Gynecologic Cancers
Ovarian cancer stands out as having one of the more striking CRP associations. A large consortium study found that women with CRP concentrations above 10 mg/L had 67 percent higher odds of ovarian cancer compared with women whose CRP was below 1 mg/L. Specific subtypes showed even more dramatic links: mucinous carcinoma odds were roughly tenfold higher, and endometrioid carcinoma odds were about three and a half times higher in the highest CRP group.9PubMed Central. High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium These very high odds ratios for rarer subtypes come from small numbers and should be interpreted cautiously, but the overall direction is consistent across studies.
Beyond risk, CRP appears to track with how gynecologic cancers progress. A meta-analysis pooling data across ovarian, endometrial, and cervical cancers found that elevated CRP was significantly associated with worse overall survival for all three cancer types.10PubMed Central. C-Reactive Protein as a Prognostic Biomarker for Gynecologic Cancers: A Meta-Analysis Endometrial cancer showed a more modest link with survival than ovarian or cervical cancer, but the pattern held across all three.
Pancreatic Cancer
Pancreatic cancer presents a more ambiguous picture. A large European nested case-control study (the EPIC cohort) found no significant association between pre-diagnostic CRP levels and pancreatic cancer risk. The odds ratio was modestly elevated but did not reach statistical significance.11PubMed Central. Inflammation marker and risk of pancreatic cancer: a nested case–control study within the EPIC cohort However, a Swedish cohort study that used a higher CRP threshold told a somewhat different story: people with CRP above 10 mg/L had about a third higher risk of pancreatic cancer compared with those below that level, though the confidence interval for that finding just barely reached statistical significance.12PubMed Central. Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study
The honest summary is that CRP may play a role in pancreatic cancer risk, but the evidence is weaker and less consistent than for colorectal or ovarian cancer. Different inflammation markers like haptoglobin and white blood cell count showed stronger links with pancreatic cancer in some of the same studies, suggesting that if inflammation contributes to this cancer, CRP is not the most sensitive marker for it.
Kidney, Bladder, and Prostate Cancers
Urological cancers have generated a growing body of CRP research, and the findings point less toward CRP as a risk predictor and more toward CRP as a gauge of how aggressive a cancer is. A comprehensive review found that CRP levels are associated with the likelihood of a prostate cancer diagnosis in men who have elevated PSA, with the probability of the cancer coming back after treatment, and with shorter survival in advanced disease. In kidney and bladder cancers, higher CRP tracked with more advanced disease stage and worse cancer-specific survival.13PubMed Central. The Role of C-Reactive Protein in Kidney, Bladder, and Prostate Cancers For kidney cancer in particular, CRP has become part of clinical scoring systems used to predict treatment outcomes, as discussed below.
Blood Cancers
In myeloma, CRP is not just a bystander marker. Research has shown that CRP in myeloma patients correlates directly with bone destruction: higher CRP tracked strongly with the number of lytic bone lesions, and bone marrow biopsies from patients with extensive bone disease contained more CRP protein within the myeloma cells themselves.14PubMed Central. C-reactive protein promotes bone destruction in human myeloma through the CD32-p38MAPK-Twist axis This suggests CRP may actively participate in one of myeloma’s most debilitating complications rather than simply reflecting it.
In lymphoma and myeloma patients more broadly, a CRP level above 54 mg/L at diagnosis was associated with nearly six times the odds of developing cachexia (severe muscle and weight loss) during treatment, and roughly triple the hazard of relapse.15PubMed Central. C-Reactive Protein Level: A Key Predictive Marker of Cachexia in Lymphoma and Myeloma Patients These are extremely high CRP values compared with the single-digit levels discussed in solid tumor risk studies, which illustrates an important point: the CRP thresholds that matter vary enormously depending on whether you are talking about predicting who develops cancer versus predicting how an already-diagnosed cancer will progress.
Upper Gastrointestinal Cancers
Esophageal and gastric cancers round out the list of malignancies where CRP has shown prognostic value. In esophageal adenocarcinoma, a meta-analysis found that elevated preoperative CRP-based scores (specifically, the Glasgow Prognostic Score, which combines CRP with albumin) predicted substantially worse survival after surgery. That study noted, however, that CRP alone was not as reliable as CRP combined with albumin for predicting outcomes in esophageal cancer.16PubMed. C-Reactive Protein and C-Reactive Protein-Based Scores to Predict Survival in Esophageal and Junctional Adenocarcinoma: Systematic Review and Meta-Analysis Research in gastric cancer has similarly shown that CRP levels tend to rise with advancing disease stage, though in this context CRP functions more as a tracking marker than a screening tool.17Journal of Surgery and Surgical Research. Can Prealbumin, Albumin and CRP Levels be used to Predict Prognosis in Patients with Gastric Cancer
How Doctors Actually Use CRP in Cancer Care
In clinical practice, CRP is almost never used on its own to diagnose or screen for cancer. A single elevated CRP reading could reflect anything from a mild infection to obesity to autoimmune disease. A Japanese study found that people with CRP above 3 mg/L had about twice the adjusted odds of having cancer compared with those under 1 mg/L, but this relationship held across many cancer types rather than pointing to any specific one, limiting its usefulness as a screening tool.18PubMed Central. High-sensitivity C-reactive protein and cancer
Where CRP has gained traction is in composite scoring systems that combine CRP with other blood markers. The most widely used is the Glasgow Prognostic Score (GPS), which pairs CRP with albumin. The logic is straightforward: an elevated CRP signals inflammation while a low albumin signals poor nutritional status, and together they capture something about a cancer patient’s overall condition that tumor stage alone misses. Studies in multiple myeloma have confirmed that GPS independently predicts survival even after adjusting for disease stage.19PubMed Central. Glasgow Prognostic Score Serves as a Prognostic Factor of Clinical Outcome in Patients with Newly Diagnosed Multiple Myeloma Modified versions incorporating additional markers like LDH have shown improved ability to sort patients into risk groups.20PubMed Central. Modified Glasgow Prognostic Score Incorporating CRP/Albumin Ratio and LDH Levels as Prognostic Indicators in Patients with Multiple Myeloma: A Retrospective Study
In metastatic kidney cancer, a study found that tracking the modified GPS during treatment actually outperformed standard imaging assessments at predicting who would survive longer. Patients classified as high-risk by their on-treatment mGPS had roughly seven and a half times the hazard of death compared with low-risk patients.21JAMA Oncology. Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell carcinoma The implication is that changes in CRP during treatment capture something about the body’s fight against cancer that a CT scan measuring tumor shrinkage does not.
CRP and Immunotherapy Response
One of the more practical recent developments is using CRP changes during immunotherapy as an early signal of whether the treatment is working. A meta-analysis across multiple cancer types found that patients with high baseline CRP before starting immune checkpoint inhibitors had about 48 percent worse overall survival and 29 percent worse progression-free survival compared with patients who started with low CRP.22PubMed Central. The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis
More interesting than the baseline level, though, is the pattern of CRP change after treatment starts. Researchers have identified what they call a “CRP flare-response”: a sharp spike in CRP during the first few weeks of immunotherapy, followed by a drop below the starting level. In non-small cell lung cancer patients, those who showed this flare-response had a median overall survival of nearly 33 months, compared with about 19 months for patients whose CRP simply declined and just under 7 months for patients whose CRP never dropped meaningfully.23Journal for ImmunoTherapy of Cancer. C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer This flare pattern has been observed across multiple cancer types and replicated in a multicenter study, where patients who showed either a CRP flare-response or a steady CRP decline below 30 percent of baseline had superior outcomes compared with CRP non-responders.24PubMed Central. Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study The flare-response pattern has also been found in gastric cancer patients treated with PD-1 inhibitors.25PubMed Central. C-reactive protein flare-response predicts the efficacy of PD-1 inhibitors in metastatic gastric cancer
This matters because oncologists currently lack good early readouts for whether immunotherapy is working. Imaging scans can be misleading in the first months because immune activation sometimes makes tumors appear to grow (a phenomenon called pseudoprogression) before they shrink. A cheap blood test like CRP that gives a signal within weeks could help doctors avoid prematurely stopping a treatment that is actually working.
Why a High CRP Does Not Mean You Have Cancer
If you have just gotten a blood test showing elevated CRP, the most likely explanation has nothing to do with cancer. CRP spikes during ordinary infections, after injuries, during autoimmune flares, and in response to conditions like obesity and smoking. Data from the CARDIA cohort, which tracked young adults over many years, found that high BMI was one of the strongest predictors of repeatedly elevated CRP, particularly in women. Nearly 70 percent of repeated CRP elevations occurred in obese women, even though they made up less than 15 percent of the study sample. Smoking, lower income, and use of sex hormones also raised the odds of elevated CRP readings.26PLOS ONE. Gender, Obesity and Repeated Elevation of C-Reactive Protein: Data from the CARDIA Cohort
This means that when a doctor orders a CRP test, they are almost never looking for cancer with it. They are typically assessing inflammation related to cardiovascular risk, infection, or autoimmune disease. An elevated result requires context: your weight, smoking status, recent illnesses, and other lab values all factor into what the number means. A CRP of 5 mg/L in an otherwise healthy, lean nonsmoker warrants more curiosity than the same number in someone with a BMI of 35 and a recent cold.
Can You Lower CRP to Reduce Cancer Risk?
This is the question most people ultimately want answered, and the evidence is less encouraging than you might hope. A year-long randomized controlled trial of aerobic exercise in previously sedentary adults found no reduction in CRP despite significant improvements in fitness, body weight, and body fat. The researchers suggested that exercise may matter more for CRP in people who start with high levels of inflammation, such as those who are obese, but for the general population, simply exercising more did not budge the number.27Cancer Epidemiology, Biomarkers & Prevention. No Reduction in C-Reactive Protein following a 12-Month Randomized Controlled Trial of Exercise in Men and Women
Weight loss tends to be more effective at lowering CRP, which makes sense given how tightly obesity and CRP track together. But no trial has yet shown that lowering CRP through any intervention reduces cancer incidence. The relationship between CRP and cancer may not be causal in the straightforward “lower CRP, lower risk” sense. CRP could be a marker of the broader inflammatory environment that promotes cancer rather than a direct driver. The distinction matters because it means focusing narrowly on CRP as a number to bring down is probably the wrong frame. Addressing the underlying sources of chronic inflammation, which for most people means managing weight, not smoking, and controlling chronic diseases, is a more productive approach than chasing CRP itself.
There is one intriguing exception in the lab: research in aggressive breast cancer cells has shown that CRP produced by the tumor cells themselves appears to directly promote their growth and blood vessel formation.8Biomolecules & Therapeutics. C-Reactive Protein Signaling Pathways in Tumor Progression – Section: BREAST CANCER If this local, tumor-produced CRP turns out to be an important driver rather than just the CRP floating in the bloodstream, it could eventually open the door to targeted therapies. For now, though, that work remains in animal models and cell cultures.